140 related articles for article (PubMed ID: 555224)
21. [Role of thalidomide in the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
[TBL] [Abstract][Full Text] [Related]
22. [Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
Locatelli F; Giovanelli E; Neretto G; Furno F; Pellerito R
Minerva Med; 1979 Mar; 70(13):925-33. PubMed ID: 220567
[TBL] [Abstract][Full Text] [Related]
23. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
24. Biology and therapy of multiple myeloma in 1996.
Barlogie B; Jagannath S; Epstein J; Munshi N; Siegel D; Desikan KR; Feinman R; Hsu PL; von Bremen K; Tricot G
Semin Hematol; 1997 Jan; 34(1 Suppl 1):67-72. PubMed ID: 9122748
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
Hungria VT; Latrilha MC; Rodrigues DG; Bydlowski SP; Chiattone CS; Maranhão RC
Cancer Chemother Pharmacol; 2004 Jan; 53(1):51-60. PubMed ID: 14574458
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma.
Cremer FW; Ehrbrecht E; Kiel K; Benner A; Hegenbart U; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2000 Oct; 26(8):851-8. PubMed ID: 11081384
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis and therapy of multiple myeloma: current aspects].
Betticher DC; Cerny T; Fey MF
Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
[TBL] [Abstract][Full Text] [Related]
28. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.
Alberts DS; Durie BG; Salmon SE
Cancer Treat Rep; 1977; 61(3):381-8. PubMed ID: 872138
[TBL] [Abstract][Full Text] [Related]
29. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
30. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
31. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
33. [Therapy of multiple myeloma and its complications].
Avvisati G; Pulsoni A; Petrucci MT; Tribalto M
Recenti Prog Med; 1990 Oct; 81(10):642-50. PubMed ID: 2291008
[TBL] [Abstract][Full Text] [Related]
34. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
35. [Multiple myeloma: current therapeutic approaches].
Troussard X; Bauduer F; Leporrier M
Bull Cancer; 1992; 79(3):231-42. PubMed ID: 1392162
[TBL] [Abstract][Full Text] [Related]
36. [Hemocytological classification, clinical staging and polychemotherapy of multiple myeloma].
István L; Karl W; Michael H; Günter A; Kelényi G; Várbíró M; Dieter R
Orv Hetil; 1983 Feb; 124(6):313-9. PubMed ID: 6835675
[No Abstract] [Full Text] [Related]
37. In vitro maintenance and retroviral transduction of human myeloma cells in long-term marrow cultures.
Stewart AK; Prince HM; Cappe D; Chu P; Lutzko C; Sutherland DR; Dubé ID
Cancer Gene Ther; 1997; 4(3):148-56. PubMed ID: 9171933
[TBL] [Abstract][Full Text] [Related]
38. Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
[TBL] [Abstract][Full Text] [Related]
39. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
Rajkumar SV; Buadi F
Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
